Multimodal imaging and detection strategy with 124 I-labeled chimeric monoclonal antibody cG250 for accurate localization and confirmation of extent of disease during laparoscopic and open surgical resection of clear cell renal cell carcinoma

Surgical Innovation

Volumn 20, Issue 1, 2013, Pages 59-69

  Povoski, Stephen P ^a   Hall, Nathan C ^a   Murrey, Douglas A ^a   Sharp, David S ^a   Hitchcock, Charles L ^a   Mojzisik, Cathy M ^a   Bahnson, Eamonn E ^a   Knopp, Michael V ^a   Martin, Edward W ^a   Bahnson, Robert R ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

image guided surgery; surgical oncology; urology

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GIRENTUXIMAB; IODINE 124;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; ENCHONDROMATOSIS; FEMALE; HEMATURIA; HIP HEMIARTHROPLASTY; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; NEPHRECTOMY; PATIENT CARE; PEROPERATIVE CARE; PREOPERATIVE CARE; TUMOR VOLUME;

ADULT; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IODINE RADIOISOTOPES; KIDNEY NEOPLASMS; LAPAROSCOPY; MALE; MIDDLE AGED; NEPHRECTOMY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; SURGERY, COMPUTER-ASSISTED;

EID: 84871725400     PISSN: 15533506     EISSN: 15533514     Source Type: Journal    
DOI: 10.1177/1553350612438416     Document Type: Article

References (66)

1. Pilcher JT. Carcinoma of the kidney. Ann Surg. 1921 ; 73: 301-309
2. Oberling C, Riviere M, Haguenau F. Ultrastructure of the clear cells in renal carcinomas and its importance for the demonstration of their renal origin. Nature. 1960 ; 186: 402-403
3. Braunstein H, Adelman JU. Histochemical study of the enzymatic activity of human neoplasms. II. Histogenesis of renal cell carcinoma. Cancer. 1966 ; 19: 935-938
4. Wallace AC, Nairn RC. Renal tubular antigens in kidney tumors. Cancer. 1972 ; 29: 977-981
5. Eble JN, Togashi K, Pisani P World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Eble JN Sauter G Epstein JI Sesterhenn IA, ed. Lyon, France: IARC Press ; 2004: 10-12.
6. SEER Program Public Use Data Tapes 1973-2002.. 2005 ;:
7. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006 ; 176 (6 pt 1). 2353-2358
8. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997 ; 183: 131-133
9. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002 ; 26: 281-291
10. Renshaw AA. Subclassification of renal cell neoplasms: an update for the practising pathologist. Histopathology. 2002 ; 41: 283-300
11. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003 ; 27: 612-624
12. Gudbjartsson T, Hardarson S, Petursdottir V, Thoroddsen A, Magnusson J, Einarsson GV. Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients. Eur Urol. 2005 ; 48: 593-600
13. Prasad SR, Humphrey PA, Catena JR, et al. Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Radiographics. 2006 ; 26: 1795-1806
14. Aydin H, Zhou M. The changing face of renal cell carcinoma pathology. Curr Oncol Rep. 2008 ; 10: 235-244
15. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer. 1986 ; 38: 489-494
16. Oosterwijk E. Carbonic anhydrase IX: historical and future perspectives. BJU Int. 2008 ; 101: 2-7
17. Grawitz P. Die sogenannten Lipome der Niere. Virchows Archiv für pathologische Anatomie und Physiologie, und für klinische Medicin. 1883 ; 93: 39-63
18. Mccormick WF, Blake CC. Some notes on Paul Grawitz and his tumor. Cancer. 1958 ; 11: 871-872
19. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol. 2010 ; 58: 75-83
20. Opavský R, Pastoreková S, Zelník V, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics. 1996 ; 33: 480-487
21. Leibovich BC, Sheinin Y, Lohse CM, et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol. 2007 ; 25: 4757-4764
22. Supuran CT Carbonic Anhydrase: Its Inhibitors and Activators. Supuran CT Scozzafava A Conway J, ed. Boca Raton, FL: CRC Press ; 2004: 1-23.
23. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000 ; 60: 7075-7083
24. Rice SL, Roney CA, Daumar P, Lewis JS. The next generation of positron emission tomography radiopharmaceuticals in oncology. Semin Nucl Med. 2011 ; 41: 265-282
25. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003 ; 9: 802-811
26. Phuoc NB, Ehara H, Gotoh T, et al. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. Oncol Rep. 2008 ; 20: 525-530
27. Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 1997 ; 57: 2827-2831
28. Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer. 2000 ; 85: 865-870
29. Bismar TA, Bianco FJ, Zhang H, et al. Quantification of G250 mRNA expression in renal epithelial neoplasms by real-time reverse transcription-PCR of dissected tissue from paraffin sections. Pathology. 2003 ; 35: 513-517
30. Oosterwijk E, Debruyne FM. Radiolabeled monoclonal antibody G250 in renal-cell carcinoma. World J Urol. 1995 ; 13: 186-190
31. Oosterwijk E, Bander NH, Divgi CR, et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol. 1993 ; 11: 738-750
32. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol. 1997 ; 15: 1529-1537
33. Steffens MG, Boerman OC, de Mulder PH, et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res. 1999 ; 5: 3268s - 3274s
34. Brouwers AH, Dorr U, Lang O, et al. 131I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study. Nucl Med Commun. 2002 ; 23: 229-236
35. Brouwers AH, Buijs WC, Oosterwijk E, et al. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. Clin Cancer Res. 2003 ; 9 (10 pt 2). 3953S - 3960S
36. Brouwers AH, Mulders PF, de Mulder PH, et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol. 2005 ; 23: 6540-6548
37. Brouwers AH, Mulders PF, Oyen WJ. Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy. J Clin Oncol. 2008 ; 26: 3808-3809
38. Pentlow KS, Graham MC, Lambrecht RM, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med. 1996 ; 37: 1557-1562
39. Herzog H, Tellman L, Qaim SM, Spellerberg S, Schmid A, Coenen HH. PET quantitation and imaging of the non-pure positron-emitting iodine isotope 124I. Appl Radiat Isot. 2002 ; 56: 673-679
40. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007 ; 8: 304-310
41. LeungK. 124I-chimeric monoclonal antibody G250. http://www.ncbi.nlm.nih. gov/books/NBK43528/. Last updated May20, 2010. Accessed October 5, 2011.
42. A comparative study of PET/CT versus diagnostic ct for the detection of clear cell renal cell carcinoma in pre-surgical patients with renal masses using iodine-124 labeled chimeric G250 (124I-cG250). http://clinicaltrials.gov/ct2/ show/NCT00606632. Accessed October 5, 2011.
43. IBA/Wilex. Redectane: pre-BLA meeting with FDA, 17June2011. http://www.wilex.de/pdf/Download/20110617-WILEX-REDECTANE-PreBLA-Press-Analyst- presentation.pdf. Accessed October 5, 2011.
44. Uzzo R, Russo P, Chen D, et al. Multicenter phase 3 REDECT trial with iodine I 124 Girentuximab-PET/CT for the presurgical detection of clear cell renal cell carcinoma (ccRCC) [abstract]. Kidney Cancer J. 2010 ; 8 79: 85
45. Strong VE, Humm J, Russo P, et al. A novel method to localize antibody-targeted cancer deposits intraoperatively using handheld PET beta and gamma probes. Surg Endosc. 2008 ; 22: 386-391
46. Bahnson EE, Murrey DA, Mojzisik CM, et al. PET/CT imaging of clear cell renal cell carcinoma with 124I labeled chimeric antibody. Ther Adv Urol. 2009 ; 1: 67-70
47. Murrey DA, Bahnson EE, Mojzisik CM, et al. Validation of targeted molecular imaging using surgical specimens: a feasibility assessment using 124I-cG250 monoclonal antibody PET/CT in clear cell renal cell carcinoma. J Am Coll Surg. 2009 ; 209: s128
48. Hall NC, Povoski SP, Murrey DA, Knopp MV, Martin EW. Combined approach of perioperative 18F-FDG PET/CT imaging and intraoperative 18F-FDG handheld gamma probe detection for tumor localization and verification of complete tumor resection in breast cancer. World J Surg Oncol. 2007 ; 5: 143
49. Povoski SP, Hall NC, Walker MJ, Martin EW. Multimodality approach of perioperative 18F-FDG PET/CT imaging, intraoperative 18F-FDG handheld gamma probe detection, and intraoperative ultrasound for tumor localization and verification of resection of all sites of hypermetabolic activity in a case of occult recurrent metastatic melanoma. World J Surg Oncol. 2008 ; 6: 1
50. Hall NC, Povoski SP, Murrey DA, Knopp MV, Martin EW. Bringing advanced medical imaging into the operative arena could revolutionize the surgical care of cancer patients. Expert Rev Med Devices. 2008 ; 5: 663-667
51. Povoski SP, Hall NC, Murrey DA, et al. Multimodal imaging and detection approach to 18F-FDG-directed surgery for patients with known or suspected malignancies: A comprehensive description of the specific methodology utilized in a single-institution cumulative retrospective experience. World J Surg Oncol. 2011 ; 9: 152
52. Otsuka H, Graham M, Kubo A, Nishitani H. Clinical utility of FDG PET. J Med Invest. 2004 ; 51: 14-19
53. Endo K, Oriuchi N, Higuchi T, et al. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol. 2006 ; 11: 286-296
54. Maldonado A, González-Alenda FJ, Alonso M, Sierra JM. PET-CT in clinical oncology. Clin Transl Oncol. 2007 ; 9: 494-505
55. Otsuka H, Morita N, Yamashita K, Nishitani H. FDG-PET/CT for cancer management. J Med Invest. 2007 ; 54: 195-199
56. Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med. 2007 ; 37: 400-419
57. Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol. 2009 ; 70: 382-392
58. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Mazière B. FDG accumulation and tumor biology. Nucl Med Biol. 1998 ; 25: 317-322
59. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998 ; 4: 1334-1336
60. Lind P, Igerc I, Beyer T, Reinprecht P, Hausegger K. Advantages and limitations of FDG PET in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging. 2004 ; 31: S125 - S134
61. Lim HS, Yoon W, Chung TW, et al. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. Radiographics. 2007 ; 27: S197 - S213
62. Metser U, Even-Sapir E. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin Nucl Med. 2007 ; 37: 206-222
63. Sun D, Bloomston M, Hinkle G, et al. Radioimmunoguided surgery (RIGS), PET/CT image-guided surgery, and fluorescence image-guided surgery: past, present, and future. J Surg Oncol. 2007 ; 96: 297-308
64. Schöder H, Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin North Am. 2008 ; 46: 225-241
65. Povoski SP, Neff RL, Mojzisik CM, et al. A comprehensive overview of radioguided surgery using gamma detection probe technology. World J Surg Oncol. 2009 ; 7: 11
66. Frangioni JV. The problem is background, not signal. Mol Imaging. 2009 ; 8: 303-304